DEVELOPMENT AND IN-VITRO CHARACTERIZATION OF SUSTAINED FLOATING HOLLOW MICROSPHERES CONTAINING LABETALOL HCL FOR THE TREATMENT OF HYPERTENSION

Aim: The present work for the development and in-vitro evaluation of sustained floating hollow microspheres (SFHM). Materials and methods: Sustained floating hollow microspheres were prepared by means of HPMC K4M, ethylcellulose and sodium alginate in various concentrations by using the solvent evaporation method using dichloromethane as solvent. The floating hollow microspheres of Labetalol HCl were formulated by the solvent evaporation method. SFHM was characterized using surface morphology by scanning electron microscopy (SEM), buoyancy studies, in-vitro floating behavior, incorporation efficiency, drug loading, production yield in-vitro drug release, and drug release kinetics studies. Results: The mean particle size ranges from 74.36± 1.02 to 102.0 ± 2.87µm. The entrapment efficiency of the drug ranges between 74.23 ± 2.12 to 80.82 ± 2.23%. The drug loading varies between 105.8 ± 1.46 to 125.2 ± 1.36µg/mg. The prepared hollow microspheres are exhibit good flowability. The in-vitro studies show release up to 12 h. The release kinetics data showed the best fit to the non-fickian release (diffusion and swelling). Conclusion: The outcomes conclude that Labetalol HCl SFHM may represent to expected option for greater bioavailability and improve patient consistency.